Natural history of mild and of moderate aortic stenosis-new insights from a large prospective european study

Current Problems in Cardiology

Volumn 38, Issue 9, 2013, Pages 365-409

  Gohlke Bärwolf, Christa ^a   Minners, Jan ^a   Jander, Nikolaus ^a   Gerdts, Eva ^a   Wachtell, Kristian ^a   Ray, Simon ^a   Pedersen, Terje R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; EUROPEAN UNION; EVENT FREE SURVIVAL; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HISTORY; HUMAN; HYPERTENSION; INCIDENCE; MULTICENTER STUDY (TOPIC); PATIENT ASSESSMENT; POPULATION RESEARCH; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; QRS COMPLEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; AORTIC VALVE; AORTIC VALVE STENOSIS; AZETIDINES; CALCINOSIS; COMORBIDITY; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84883186624     PISSN: 01462806     EISSN: 15356280     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2013.06.003     Document Type: Article

References (124)

1. Laslett L.J., Alagona P., Clark B.A., et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol 2012, 60:S1-49.
2. National Center for Health Statistics US: Deaths: data for 2008. National Vital Statistics Reports (NVSR), 2010.
3. Roberts W.C., Ko J.M. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 2005, 111:920-925.
4. Berry C., Lloyd S.M., Wang Y., Macdonald A., Ford I. The changing course of aortic valve disease in Scotland: temporal trends in hospitalizations and mortality and prognostic importance of aortic stenosis. Eur Heart J 2013, 34:1538-1547.
5. Iung B., Baron G., Butchart E.G., et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on valvular heart disease. Eur Heart J 2003, 24:1231-1243.
6. Otto C.M., Kuusisto J., Reichenbach D.D., Gown A.M., O'Brien K.D. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994, 90:844-853.
7. O'Brien K.D., Kuusisto J., Reichenbach D.D., et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 1995, 92:2163-2168.
8. Rajamannan N.M., Evans F.J., Aikawa E., et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease-2011 update. Circulation 2011, 124:1783-1791.
9. Stewart B.F., Siscovick D., Lind B.K., et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997, 29:630-634.
10. Pohle K., Maffert R., Ropers D., et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001, 104:1927-1932.
11. Katz R., Wong N.D., Kronmal R., et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 2006, 113:2113-2119.
12. Owens D.S., Katz R., Takasu J., Kronmal R., Budoff M.J., O'Brien K.D. Incidence and progression of aortic valve calcium in the Multi-ethnic Study of Atherosclerosis (MESA). Am J Cardiol 2010, 105:701-708.
13. Cosmi J.E., Kort S., Tunick P.A., et al. The risk of the development of aortic stenosis in patients with "benign" aortic valve thickening. Arch Intern Med 2002, 162:2345-2347.
14. Thanassoulis G., Campbell C.Y., Owens D.S., et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013, 368:503-512.
15. Lindroos M., Kupari M., Heikkila J., Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993, 21:1220-1225.
16. Otto C.M., Lind B.K., Kitzman D.W., Gersh B.J., Siscovick D.S. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999, 341:142-147.
17. Gharacholou S.M., Karon B.L., Shub C., Pellikka P.A. Aortic valve sclerosis and clinical outcomes: moving toward a definition. Am J Med 2011, 124:103-110.
18. Authors/Task Force M., Vahanian A., Alfieri O., et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012, 33:2451-2496.
19. Bonow R.O., Carabello B.A., Chatterjee K., et al. Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008, 118:e523-e661.
20. Baumgartner H., Hung J., Bermejo J., et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiogr 2009, 10:1-25.
21. Nkomo V.T., Gardin J.M., Skelton T.N., Gottdiener J.S., Scott C.G., Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006, 368:1005-1011.
22. Livanainen A.M., Lindroos M., Tilvis R., Heikkila J., Kupari M. Natural history of aortic valve stenosis of varying severity in the elderly. Am J Cardiol 1996, 78:97-101.
23. Eveborn G.W., Schirmer H., Heggelund G., Lunde P., Rasmussen K. The evolving epidemiology of valvular aortic stenosis. The Tromso Study. Heart 2013, 99:396-400.
24. Census BUS. Annual estimates of the resident population by sex and five-year age groups for the United States: April 1, 2000 to July 1, 2009 (NC-EST2009-01), in SAotUSPD, ed., 2010.
25. Chandra H.R., Goldstein J.A., Choudhary N., et al. Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. J Am Coll Cardiol 2004, 43:169-175.
26. Ross J., Braunwald E. Aortic stenosis. Circulation 1968, 38:61-67.
27. Rosenhek R., Binder T., Porenta G., et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000, 343:611-617.
28. Rosenhek R., Zilberszac R., Schemper M., et al. Natural history of very severe aortic stenosis. Circulation 2010, 121:151-156.
29. Otto C.M., Burwash I.G., Legget M.E., et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997, 95:2262-2270.
30. Pellikka P.A., Sarano M.E., Nishimura R.A., et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 2005, 111:3290-3295.
31. Rahimtoola S.H. Valvular heart disease: a perspective on the asymptomatic patient with severe valvular aortic stenosis. Eur Heart J 2008, 29:1783-1790.
32. Horstkotte D., Loogen F. The natural history of aortic valve stenosis. Eur Heart J 1988, 9(suppl E):57-64.
33. Kennedy K.D., Nishimura R.A., Holmes D.R., Bailey K.R. Natural history of moderate aortic stenosis. J Am Coll Cardiol 1991, 17:313-319.
34. Rosenhek R., Klaar U., Schemper M., et al. Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. Eur Heart J 2004, 25:199-205.
35. Kearney L.G., Ord M., Buxton B.F., et al. Progression of aortic stenosis in elderly patients over long-term follow up. Int J Cardiol 2012, 10.1016/j.icard.2012.03.139.
36. Yechoor P., Blaustein A.S., Bakaeen F.G., et al. The natural history of moderate aortic stenosis in a veteran population. J Thorac Cardiovasc Surg 2013, 145:1550-1553.
37. Rossebø A.B., Pedersen T.R., Boman K., et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343-1356.
38. Minners J. Outcome in 1763 asymptomatic patients with mild or moderate calcific aortic stenosis followed prospectively with annual echocardiography EHJ, ESC abstract 2013, submitted 2013.
39. Otto C.M. Aortic stenosis: even mild disease is significant. Eur Heart J 2004, 25:185-187.
40. group Ss Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
41. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
42. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001-1009.
43. Otto C.M. Aortic stenosis and hyperlipidemia: establishing a cause-effect relationship. Am Heart J 2004, 147:761-763.
44. Rajamannan N.M., Subramaniam M., Springett M., et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 2002, 105:2660-2665.
45. Rajamannan N.M., Subramaniam M., Rickard D., et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003, 107:2181-2184.
46. Rossebø A.B., Pedersen T.R., Allen C., et al. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol 2007, 99:970-973.
47. Lund B.P., Gohlke-Barwolf C., Cramariuc D., Rossebø A.B., Rieck A.E., Gerdts E. Effect of obesity on left ventricular mass and systolic function in patients with asymptomatic aortic stenosis (a Simvastatin Ezetimibe in Aortic Stenosis [SEAS] substudy). Am J Cardiol 2010, 105:1456-1460.
48. Cramariuc D., Rieck A.E., Staal E.M., et al. Factors influencing left ventricular structure and stress-corrected systolic function in men and women with asymptomatic aortic valve stenosis (a SEAS substudy). Am J Cardiol 2008, 101:510-515.
49. Gerdts E., Rossebø A.B., Pedersen T.R., et al. Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study). Am J Cardiol 2010, 106:1634-1639.
50. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463.
51. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986, 57:450-458.
52. de Simone G., Izzo R., Chinali M., et al. Does information on systolic and diastolic function improve prediction of a cardiovascular event by left ventricular hypertrophy in arterial hypertension?. Hypertension 2010, 56:99-104.
53. Tuseth N., Cramariuc D., Rieck A.E., Wachtell K., Gerdts E. Asymmetric septal hypertrophy-a marker of hypertension in aortic stenosis (a SEAS substudy). Blood Press 2010, 19:140-144.
54. Briand M., Dumesnil J.G., Kadem L., et al. Reduced systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment. J Am Coll Cardiol 2005, 46:291-298.
55. Lancellotti P., Donal E., Magne J., et al. Impact of global left ventricular afterload on left ventricular function in asymptomatic severe aortic stenosis: a two-dimensional speckle-tracking study. Eur J Echocardiogr 2010, 11:537-543.
56. Garcia D., Pibarot P., Dumesnil J.G., Sakr F., Durand L.G. Assessment of aortic valve stenosis severity: a new index based on the energy loss concept. Circulation 2000, 101:765-771.
57. Bahlmann E., Cramariuc D., Gerdts E., et al. Impact of pressure recovery on echocardiographic assessment of asymptomatic aortic stenosis: a SEAS substudy. JACC Cardiovasc Imaging 2010, 3:555-562.
58. Rieck A.E., Cramariuc D., Boman K., et al. Hypertension in aortic stenosis: implications for left ventricular structure and cardiovascular events. Hypertension 2012, 60:90-97.
59. Nistri S., Faggiano P., Olivotto I., et al. Hemodynamic progression and outcome of asymptomatic aortic stenosis in primary care. Am J Cardiol 2012, 109:718-723.
60. Greve A.M., Gerdts E., Boman K., et al. Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. Int J Cardiol 2013, 166:72-76.
61. Greve A.M., Boman K., Gohlke-Baerwolf C., et al. Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. Circulation 2012, 125:346-353.
62. Holme I., Pedersen T.R., Boman K., et al. A risk score for predicting mortality in patients with asymptomatic mild to moderate aortic stenosis. Heart 2012, 98:377-383.
63. Cowell S.J., Newby D.E., Prescott R.J., et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005, 352:2389-2397.
64. Chan K.L., Teo K., Dumesnil J.G., Ni A., Tam J. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010, 121:306-314.
65. Antonini-Canterin F., Hirsu M., Popescu B.A., et al. Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am J Cardiol 2008, 102:738-742.
66. Cholesterol Treatment Trialists, Baigent C., Blackwell L., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
67. Cholesterol Treatment Trialists C, Mihaylova B., Emberson J., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590.
68. Holme I., Boman K., Brudi P., et al. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. Am J Cardiol 2010, 105:1802-1808.
69. Peter M., Hoffmann A., Parker C., Luscher T., Burckhardt D. Progression of aortic stenosis. Role of age and concomitant coronary artery disease. Chest 1993, 103:1715-1719.
70. Faggiano P., Ghizzoni G., Sorgato A., et al. Rate of progression of valvular aortic stenosis in adults. Am J Cardiol 1992, 70:229-233.
71. Kume T., Kawamoto T., Akasaka T., et al. Rate of progression of valvular aortic stenosis in patients undergoing dialysis. J Am Soc Echocardiogr 2006, 19:914-918.
72. Yilmaz M.B., Guray U., Guray Y., et al. Lipid profile of patients with aortic stenosis might be predictive of rate of progression. Am Heart J 2004, 147:915-918.
73. Kamalesh M., Ng C., El Masry H., Eckert G., Sawada S. Does diabetes accelerate progression of calcific aortic stenosis?. Eur J Echocardiogr 2009, 10:723-725.
74. Briand M., Lemieux I., Dumesnil J.G., et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 2006, 47:2229-2236.
75. Bahler R.C., Desser D.R., Finkelhor R.S., Brener S.J., Youssefi M. Factors leading to progression of valvular aortic stenosis. Am J Cardiol 1999, 84:1044-1048.
76. Palta S., Pai A.M., Gill K.S., Pai R.G. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 2000, 101:2497-2502.
77. Ngo M.V., Gottdiener J.S., Fletcher R.D., Fernicola D.J., Gersh B.J. Smoking and obesity are associated with the progression of aortic stenosis. Am J Geriatr Cardiol 2001, 10:86-90.
78. Rahimtoola S.H. Should patients with asymptomatic mild or moderate aortic stenosis undergoing coronary artery bypass surgery also have valve replacement for their aortic stenosis?. Heart 2001, 85:337-341.
79. Beach J.M., Mihaljevic T., Svensson L.G., et al. Coronary artery disease and outcomes of aortic valve replacement for severe aortic stenosis. J Am Coll Cardiol 2013, 61:837-848.
80. Mancia G., Laurent S., Agabiti-Rosei E., et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009, 27:2121-2158.
81. Antonini-Canterin F., Huang G., Cervesato E., et al. Symptomatic aortic stenosis: does systemic hypertension play an additional role?. Hypertension 2003, 41:1268-1272.
82. Linhartova K., Filipovsky J., Cerbak R., Sterbakova G., Hanisova I., Beranek V. Severe aortic stenosis and its association with hypertension: analysis of clinical and echocardiographic parameters. Blood Press 2007, 16:122-128.
83. Aurigemma G.P., Silver K.H., Priest M.A., Gaasch W.H. Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol 1995, 26:195-202.
84. Hachicha Z., Dumesnil J.G., Pibarot P. Usefulness of the valvuloarterial impedance to predict adverse outcome in asymptomatic aortic stenosis. J Am Coll Cardiol 2009, 54:1003-1011.
85. Bermejo J. The effects of hypertension on aortic valve stenosis. Heart 2005, 91:280-282.
86. Kadem L., Dumesnil J.G., Rieu R., Durand L.G., Garcia D., Pibarot P. Impact of systemic hypertension on the assessment of aortic stenosis. Heart 2005, 91:354-361.
87. Kannel W.B. Blood pressure as a cardiovascular risk factor: prevention and treatment. J Am Med Assoc 1996, 275:1571-1576.
88. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Prospective Studies C. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
89. O'Brien K.D., Zhao X.Q., Shavelle D.M., et al. Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J Invest Med 2004, 52:185-191.
90. Chockalingam A., Venkatesan S., Subramaniam T., et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am Heart J 2004, 147:E19.
91. Nadir M.A., Wei L., Elder D.H., et al. Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. J Am Coll Cardiol 2011, 58:570-576.
92. deFilippi C.R., Willett D.L., Brickner M.E., et al. Usefulness of dobutamine echocardiography in distinguishing severe from nonsevere valvular aortic stenosis in patients with depressed left ventricular function and low transvalvular gradients. Am J Cardiol 1995, 75:191-194.
93. Connolly H.M., Oh J.K., Schaff H.V., et al. Severe aortic stenosis with low transvalvular gradient and severe left ventricular dysfunction:result of aortic valve replacement in 52 patients. Circulation 2000, 101:1940-1946.
94. Schwammenthal E., Vered Z., Moshkowitz Y., et al. Dobutamine echocardiography in patients with aortic stenosis and left ventricular dysfunction: predicting outcome as a function of management strategy. Chest 2001, 119:1766-1777.
95. Monin J.L., Quere J.P., Monchi M., et al. Low-gradient aortic stenosis: operative risk stratification and predictors for long-term outcome: a multicenter study using dobutamine stress hemodynamics. Circulation 2003, 108:319-324.
96. Clavel M.A., Fuchs C., Burwash I.G., et al. Predictors of outcomes in low-flow, low-gradient aortic stenosis: results of the multicenter TOPAS Study. Circulation 2008, 118:S234-S242.
97. 2. JACC Cardiovasc Imaging 2010, 3:563-566.
98. Minners J., Allgeier M., Gohlke-Baerwolf C., Kienzle R.P., Neumann F.J., Jander N. Inconsistencies of echocardiographic criteria for the grading of aortic valve stenosis. Eur Heart J 2008, 29:1043-1048.
99. Cramariuc D., Cioffi G., Rieck Ashild E., et al. Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS substudy. J Am Coll Cardiol Imaging 2009, 2:390-399.
100. Jander N., Minners J., Holme I., et al. Outcome of patients with low-gradient "severe" aortic stenosis and preserved ejection fraction. Circulation 2011, 123:887-895.
101. Minners J., Allgeier M., Gohlke-Baerwolf C., Kienzle R.P., Neumann F.J., Jander N. Inconsistent grading of aortic valve stenosis by current guidelines: haemodynamic studies in patients with apparently normal left ventricular function. Heart 2010, 96:1463-1468.
102. Dumesnil J.G., Pibarot P., Carabello B. Paradoxical low flow and/or low gradient severe aortic stenosis despite preserved left ventricular ejection fraction: implications for diagnosis and treatment. Eur Heart J 2010, 31:281-289.
103. Adda J., Mielot C., Giorgi R., et al. Low-flow, low-gradient severe aortic stenosis despite normal ejection fraction is associated with severe left ventricular dysfunction as assessed by speckle-tracking echocardiography: a multicenter study. Circ Cardiovasc Imaging 2012, 5:27-35.
104. Lancellotti P., Magne J., Donal E., et al. Clinical outcome in asymptomatic severe aortic stenosis: insights from the new proposed aortic stenosis grading classification. J Am Coll Cardiol 2012, 59:235-243.
105. Hachicha Z., Dumesnil J.G., Bogaty P., Pibarot P. Paradoxical low-flow, low-gradient severe aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival. Circulation 2007, 115:2856-2864.
106. Barasch E., Fan D., Chukwu E.O., et al. Severe isolated aortic stenosis with normal left ventricular systolic function and low transvalvular gradients: pathophysiologic and prognostic insights. J Heart Valve Dis 2008, 17:81-88.
107. Tarantini G., Covolo E., Razzolini R., et al. Valve replacement for severe aortic stenosis with low transvalvular gradient and left ventricular ejection fraction exceeding 0.50. Ann Thorac Surg 2011, 91:1808-1815.
108. Clavel M.A., Dumesnil J.G., Capoulade R., Mathieu P., Senechal M., Pibarot P. Outcome of patients with aortic stenosis, small valve area, and low-flow, low-gradient despite preserved left ventricular ejection fraction. J Am Coll Cardiol 2012, 60:1259-1267.
109. Baumgartner H., Kratzer H., Helmreich G., Kuehn P. Determination of aortic valve area by Doppler echocardiography using the continuity equation: a critical evaluation. Cardiology 1990, 77:101-111.
110. Jander N. Low-gradient 'severe' aortic stenosis with preserved ejection fraction: new entity, or discrepant definitions? Eur Heart J Suppl 2008;10:E11-E15.
111. Carabello B.A. Clinical practice. Aortic stenosis. N Engl J Med 2002, 346:677-682.
112. Carroll J.D., Carroll E.P., Feldman T., et al. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 1992, 86:1099-1107.
113. Chung A.K., Das S.R., Leonard D., et al. Women have higher left ventricular ejection fractions than men independent of differences in left ventricular volume: the Dallas Heart Study. Circulation 2006, 113:1597-1604.
114. 1988 PotVCS Clinical, haemodynamic and angiographic predictors of survival in unoperated patients with aortic stenosis. The VA Cooperative Study on Valvular Heart Disease. Eur Heart J 1988, 9(suppl E):65-69.
115. Herrmann S., Stork S., Niemann M., et al. Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. J Am Coll Cardiol 2011, 58:402-412.
116. Cueff C., Serfaty J.M., Cimadevilla C., et al. Measurement of aortic valve calcification using multislice computed tomography: correlation with haemodynamic severity of aortic stenosis and clinical implication for patients with low ejection fraction. Heart 2011, 97:721-726.
117. Otto C.M. Valvular aortic stenosis: disease severity and timing of intervention. J Am Coll Cardiol 2006, 47:2141-2151.
118. Fuster V., Ryden L.E., Cannom D.S., et al. ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011, 57:e101-e198.
119. Bang CN, Dalsgaard M, Greve AM, et al. Left atrial size and function as predictors of new-onset of atrial fibrillation in patients with asymptomatic aortic stenosis: the simvastatin and ezetimibe in aortic stenosis study [published online ahead of print February 14, 2013]. Int J Cardiol. doi: 10.1016/j.ijcard.2013.01.060.
120. Sorgato A., Faggiano P., Aurigemma G.P., Rusconi C., Gaasch W.H. Ventricular arrhythmias in adult aortic stenosis: prevalence, mechanisms, and clinical relevance. Chest 1998, 113:482-491.
121. Lund O., Nielsen T.T., Emmertsen K., et al. Mortality and worsening of prognostic profile during waiting time for valve replacement in aortic stenosis. Thorac Cardiovasc Surg 1996, 44:289-295.
122. Hering D., Piper C., Horstkotte D. Influence of atypical symptoms and electrocardiographic signs of left ventricular hypertrophy or ST-segment/T-wave abnormalities on the natural history of otherwise asymptomatic adults with moderate to severe aortic stenosis: preliminary communication. J Heart Valve Dis 2004, 13:182-187.
123. Nair C.K., Sketch M.H., Ahmed I., et al. Calcific valvular aortic stenosis with and without mitral anular calcium. Am J Cardiol 1987, 60:865-870.
124. Chugh S.S., Jui J., Gunson K., et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol 2004, 44:1268-1275.